Cosmo Pharmaceuticals (OTC:CMOPF) Trading Down 3.9% – Time to Sell?

Cosmo Pharmaceuticals (OTC:CMOPF)’s share price dropped 3.9% during trading on Tuesday . The company traded as low as C$66.93 and last traded at C$66.93. Approximately 76 shares were traded during trading, a decline of 71% from the average daily volume of 259 shares. The stock had previously closed at C$69.62.

Cosmo Pharmaceuticals Price Performance

The firm’s 50 day moving average is C$84.69 and its two-hundred day moving average is C$85.24.

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy.